CPT code 83916 denotes an immunologic laboratory assay measuring oligoclonal bands in cerebrospinal fluid with a paired serum specimen. This test is clinically important for evaluating patients with suspected inflammatory central nervous system disorders, most notably multiple sclerosis, because the presence of CSF-restricted oligoclonal bands supports a diagnosis of intrathecal immunoglobulin production. Nationally, the test is performed in hospital and reference clinical laboratories and factors into diagnostic pathways for neurology and infectious disease evaluations.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context and typical sites of service, benchmarks and utilization patterns where available, and notes on common billing and coverage considerations for this laboratory procedure. The content clarifies what the code represents, why it matters to providers and payers, and what aspects of coding and service delivery are typically relevant for reimbursement and clinical documentation.

Data not available in the input includes specific payer policy details, associated taxonomies, related CPT or ICD-10 codes, and precise utilization benchmarks. The publication focuses on the clinical role of the assay and practical billing metadata for CPT code 83916 at a national level.